Home > Journals > International Angiology > Past Issues > Articles online first > International Angiology 2016 Jun 16





A Journal on Angiology

Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899



International Angiology 2016 Jun 16

language: English

Sulodexide and phlebotonics in the treatment of venous ulcer


San Luis Rio Colorado, Baja California, Mexico


BACKGROUND: In the treatment of venous leg ulcers, vasoactive drugs such as diosmin-hesperidin micronized purified flavonoids (DH), and recently sulodexide (SDX), have been used besides compression therapy and local measures. The purpose of this study is to investigate whether administering both drugs SDX and DH is better than DH alone in the treatment of venous ulcer.
METHODS: In an open-label, observational, non-parallel trial, 70 patients with 90 venous ulcers were treated with multi-layer bandaging, local measures and DH, 37 patients (50 ulcers) also received SDX, 33 patients (40 ulcers) without SDX were the control group. The evolution of leg ulcers and lipodermatosclerosis was evaluated by computerized imaging measurement.
RESULTS: The initial clinical characteristics of both groups were similar. Ulcer size showed a faster reduction in the group receiving SDX (p<0.01). With SDX, all of the ulcers were healed by week 12, in the control group, all ulcers were healed at week 21 (p<0.01 between groups). Lipodermatosclerosis improved in both groups, but it decreased faster in the SDX group. No adverse effects attributed to the medications were seen in either group.
CONCLUSIONS: The administration of sulodexide and diosmin-hesperidin was effective in accelerating ulcer healing, controlling pain and improving lipodermatosclerosis.

top of page

Publication History

Cite this article as

Corresponding author e-mail